These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 33640051)

  • 21. Inequitable COVID-19 vaccine distribution and the intellectual property rights prolong the pandemic.
    Altindis E
    Expert Rev Vaccines; 2022 Apr; 21(4):427-430. PubMed ID: 34878957
    [No Abstract]   [Full Text] [Related]  

  • 22. Exploring risks of investor claims brought forth after the TRIPS waiver for COVID-19.
    Kulkarni SM; Kaur V
    Pharm Pat Anal; 2022 Nov; 11(6):165-174. PubMed ID: 36314462
    [TBL] [Abstract][Full Text] [Related]  

  • 23. COVID-19 vaccines and treatments: When speed is necessary and not enough.
    Grasela TH; Price DA; Wagner JA
    Clin Transl Sci; 2021 Jul; 14(4):1201-1205. PubMed ID: 33834614
    [No Abstract]   [Full Text] [Related]  

  • 24. Intellectual Property and the Politics of Public Good during COVID-19: Framing Law, Institutions, and Ideas during TRIPS Waiver Negotiations at the WTO.
    Fischer SE; Vitale L; Agutu AL; Kavanagh MM
    J Health Polit Policy Law; 2024 Feb; 49(1):9-42. PubMed ID: 37522338
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Financing and protection for the health and care workforce.
    Campbell J; Koca F
    Bull World Health Organ; 2021 Jan; 99(1):2. PubMed ID: 33716330
    [No Abstract]   [Full Text] [Related]  

  • 26. 2021 FDA approvals: value driven by COVID-19 vaccines.
    Baedeker M; Ringel MS; Schulze U
    Nat Rev Drug Discov; 2022 Feb; 21(2):90. PubMed ID: 35039671
    [No Abstract]   [Full Text] [Related]  

  • 27. Cash payments in Africa could boost vaccine uptake.
    Arezki R
    Nature; 2021 Aug; 596(7870):9. PubMed ID: 34345045
    [No Abstract]   [Full Text] [Related]  

  • 28. Omicron is bad but the global response is worse.
    Nature; 2021 Dec; 600(7888):190. PubMed ID: 34876667
    [No Abstract]   [Full Text] [Related]  

  • 29. COVID-19 in the Caribbean.
    Burki TK
    Lancet Respir Med; 2021 Apr; 9(4):e46. PubMed ID: 33581745
    [No Abstract]   [Full Text] [Related]  

  • 30. Is there light at the end of the Covid-19 tunnel?
    Mortimer PP
    Rev Med Virol; 2021 May; 31(3):e2173. PubMed ID: 33002254
    [No Abstract]   [Full Text] [Related]  

  • 31. Brazil needs a coordinated and cooperative approach to tackle COVID-19.
    Barberia LG; Costa SF; Sabino EC
    Nat Med; 2021 Jul; 27(7):1133-1134. PubMed ID: 34155412
    [No Abstract]   [Full Text] [Related]  

  • 32. COVID is here to stay: countries must decide how to adapt.
    Nature; 2022 Jan; 601(7892):165. PubMed ID: 35013606
    [No Abstract]   [Full Text] [Related]  

  • 33. Access considerations for a COVID-19 vaccine for South Africa.
    Bangalee V; Suleman F
    S Afr Fam Pract (2004); 2020 Oct; 62(1):e1-e4. PubMed ID: 33179954
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A Needle in a Haystack? Human Rights Framing at the World Trade Organization for Access to COVID-19 Vaccines.
    Perehudoff K; Qazilbash H; de Vries KF
    Health Hum Rights; 2022 Dec; 24(2):141-157. PubMed ID: 36579306
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Time is running out for COVID vaccine patent waivers.
    Nature; 2022 Mar; 603(7903):764. PubMed ID: 35352056
    [No Abstract]   [Full Text] [Related]  

  • 36. Follow the Money: Childhood Health Care Disparities Magnified by COVID-19.
    Pavlakis S; Roach ES
    Pediatr Neurol; 2021 May; 118():32-34. PubMed ID: 33744477
    [No Abstract]   [Full Text] [Related]  

  • 37. Challenges in the rollout of COVID-19 vaccines worldwide.
    Burki TK
    Lancet Respir Med; 2021 Apr; 9(4):e42-e43. PubMed ID: 33684355
    [No Abstract]   [Full Text] [Related]  

  • 38. A "No More Waves" strategy for COVID-19 in Canada.
    Morris AM; Mintz JM
    CMAJ; 2021 Jan; 193(4):E132-E134. PubMed ID: 33298403
    [No Abstract]   [Full Text] [Related]  

  • 39. A network analysis of COVID-19 mRNA vaccine patents.
    Gaviria M; Kilic B
    Nat Biotechnol; 2021 May; 39(5):546-548. PubMed ID: 33981074
    [No Abstract]   [Full Text] [Related]  

  • 40. Improving Access to COVID-19 Vaccines: An Analysis of TRIPS Waiver Discourse among WTO Members, Civil Society Organizations, and Pharmaceutical Industry Stakeholders.
    Kohler J; Wong A; Tailor L
    Health Hum Rights; 2022 Dec; 24(2):159-175. PubMed ID: 36579316
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.